AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2486590
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine + 1 mg butorphanol (Group I)
Trial: 2486590
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine + 2 mg butorphanol (Group II)
Trial: 2486590
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine + 2 mg morphine (Group III)
Trial: 25412300
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise program (EX), combining continuous steady-state and interval cycling at various intensities, in combination with unsupervised moderate intensity aerobic activity and conventional diabetic management
Trial: 23470235
Drug: Sertaconazole 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertaconazole 2% cream applied twice daily for 1 month
Trial: 23470235
Drug: Hydrocortisone 1%
RxNorm normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 1% ointment applied twice daily for 1 month
Trial: 21528627
Drug: Low-intensity vibration
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity vibration (LIV) at 0.27 +/- 0.11 g; 34 Hz
Trial: 21528627
Drug: Low-intensity vibration
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity vibration (LIV) at 0.44 +/- 0.18 g; 34 Hz
Trial: 11783255
Drug: Sini Decoction
RxNorm normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sini Decoction (SND), 25 ml daily from 3 days before operation to the third day after operation.
Trial: 2551560
Drug: Dilevalol (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol (25, 50, and 50 mg bolus injections at 15-minute intervals)
Trial: 31693083
Drug: Stellate Ganglion
RxNorm normalized name: Mastocarpus stellatus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stellate Ganglion Block (SGB) treatment
Trial: 26887208
Drug: Heat-sensitive moxibustion
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-sensitive moxibustion applied to Guanyuan (GV 4) for 40 min, once daily for (7 +/- 2) days in one menstrual cycle, for 3 menstrual cycles.
Trial: 16289676
Drug: Bio-adhesive 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-adhesive 0.2% chlorhexidine gel applied once during surgery
Trial: 16289676
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied once during surgery
Trial: 12478901
Drug: rhIL-11 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-11 (50 micrograms/kg/d) administered subcutaneously for 14 consecutive days after chemotherapy
Trial: 1600052
Drug: Lansoprazole (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (all doses)
Trial: 2122719
Drug: Lactase-containing tablets
RxNorm normalized name: Lactase
DrugBank: Tilactase (DB13761)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactase-containing tablets
Trial: 30377198
Drug: Epacadostat (IDO1-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat (IDO1-selective inhibitor) in combination with pembrolizumab
Trial: 21276122
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of lycopene for 12 weeks
Trial: 19738090
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) algorithm for antibiotic administration
Trial: 15499533
Drug: Dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DP) at 6.4 mg/kg DHA
Trial: 15499533
Drug: Dihydroartemisinin-piperaquine plus
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine plus additional artemisinin derivative (DP+) at 12 mg/kg
Trial: 2971549
Drug: Doxazosin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (mean final daily dose: 13.1 mg)
Trial: 24929949
Drug: fosamprenavir/ritonavir 700/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosamprenavir/ritonavir 700/100 mg b.i.d. for 16 days with a single dose of olanzapine 15 mg on Day 13
Trial: 24929949
Drug: olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olanzapine 10 mg alone
Trial: 12442349
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg via 15 min infusion every 3-4 weeks)
Trial: 12442349
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg via 2 hr infusion)
Trial: 10456490
Drug: Control (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (200 ml orange juice)
Trial: 445503
Drug: Cyclophosphamide alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide alone (1 g/m2)
Trial: 445503
Drug: Cyclophosphamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (500 mg/m2) plus Adriamycin (40 mg/m2)
Trial: 445503
Drug: Combination regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimen (Cyclophosphamide plus Adriamycin)
Trial: 30202898
Drug: Sequential Monte
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Monte-G HC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Monte Carlo adaptation for updating posterior distribution
Trial: 31109746
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment after SF aspiration
Trial: 29878718
Drug: Double diluted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double diluted abobotulinum toxin type A (Dysport) (dilution of 15 mL to give 3.33 units per 0.1 mL)
Trial: 29878718
Drug: Common concentration
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common concentration of abobotulinum toxin type A (Dysport) (dilution of 7.5 mL to give 6.67 units per 0.1 mL)
Trial: 17587751
Drug: Olmesartan 40
RxNorm normalized name: HCTZ 25/OLMESARTAN 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 40 mg once daily
Trial: 17083180
Drug: Chiropractic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic treatment (8 modes)
Trial: 8796182
Drug: High-dose FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose FSH (150 IU)
Trial: 8796182
Drug: Low-dose FSH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose FSH
Trial: 1643014
Drug: Conventional-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional-dose cytarabine (200 mg/m2/d by continuous infusion)
Trial: 1643014
Drug: Intermediate-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose cytarabine (500 mg/m2 every 12 h)
Trial: 29326183
Drug: Laparoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic treatment (control)
Trial: 18351298
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention (only instructed to instil bimatoprost daily)
Trial: 18351298
Drug: Bimatoprost therapy
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost therapy
Trial: 10384851
Drug: Naseptin antiseptic
RxNorm normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naseptin antiseptic nasal carrier cream alone (Group A)
Trial: 10384851
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Naseptin cream and silver nitrate cautery (Group B)
Trial: 10384851
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of age groups in both treatment arms
Trial: 2050827
Drug: Procainamide (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procainamide (750 mg IV) with probenecid (2 g orally)
Trial: 2050827
Drug: Procainamide (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procainamide (750 mg IV) without probenecid
Trial: 31781762
Drug: Ganciclovir preemptive
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir preemptive therapy
Trial: 30962677
Drug: Aprocitentan 100
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprocitentan 100 mg once a day (qd)
Trial: 30962677
Drug: Aprocitentan 25
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprocitentan 25 mg and above
Trial: 30962677
Drug: Aprocitentan up
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprocitentan up to 10 µg/mL
Trial: 30962677
Drug: Aprocitentan (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprocitentan (single and multiple doses)
Trial: 30962677
Drug: Aprocitentan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprocitentan (100 mg qd)
Trial: 25624076
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (0.3mg/kg)
Trial: 25624076
Drug: Morphine (0.1mg/kg)
RxNorm normalized name: morphine 0.23 MG
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (0.1mg/kg)
Trial: 23266359
Drug: 8mg fesoterodine
RxNorm normalized name: fesoterodine fumarate 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8mg fesoterodine tablet formulation (test)
Trial: 23266359
Drug: 8mg fesoterodine
RxNorm normalized name: fesoterodine fumarate 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8mg fesoterodine tablet formulation (reference)
Trial: 15472806
Drug: Anidulafungin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anidulafungin (100 mg on day 1, followed by 50 mg per day)
Trial: 15472806
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg on day 1, followed by 100 mg per day)
Trial: 8489556
Drug: MDL 72974A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDL 72974A (doses > or = 0.5 mg)
Trial: 8489556
Drug: MDL 72974A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDL 72974A (multiple doses)
Trial: 8489556
Drug: MDL 72974A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDL 72974A (single oral dose)
Trial: 28074483
Drug: Randomisation to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomisation to opposite treatment groups
Trial: 17205304
Drug: Drinking solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking solution (formulation 1)
Trial: 17205304
Drug: Capsule formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulation 2B
Trial: 17205304
Drug: Capsule formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulation 2C
Trial: 9832300
Drug: Troglitazone 400
RxNorm normalized name: troglitazone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 400 mg single dose
Trial: 8607318
Drug: Thiopentone 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone 5.0 mg/kg
Trial: 8607318
Drug: Thiopentone 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone 6.0 mg/kg
Trial: 2693440
Drug: Gugulipid (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gugulipid (500 mg tds for 12 weeks after 8 weeks of diet and placebo)
Trial: 28260223
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of solifenacin 5‐mg tablets and pregabalin 75‐mg capsules bid (Group A)
Trial: 28260223
Drug: Solifenacin 5‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5‐mg tablets (Group B)
Trial: 28260223
Drug: Pregabalin 75‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75‐mg capsules bid (Group C)
Trial: 17509580
Drug: Estro-progestin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estro-progestin treatment (2 mg of hemihydrate E(2) and 10 mg of dydrogesterone in a continuous sequential regimen)
Trial: 12768153
Drug: Oxiplex/SP Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiplex/SP Gel (1-3 mL)
Trial: 10681072
Drug: Mibefradil (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil (50-100 mg)
Trial: 9501335
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (0.15-0.17 mg/m3)
Trial: 9501335
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (0.03-0.08 mg/m3)
Trial: 9501335
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (0.02-0.03 mg/m3)
Trial: 1439620
Drug: Arthrotec (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrotec (50 mg diclofenac and 200 micrograms misoprostol)
Trial: 1439620
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac (control)
Trial: 1439620
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (Arthrotec and diclofenac)
Trial: 30024627
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin A soft capsules for 7 days
Trial: 30024627
Drug: Conventional anti‐inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anti‐inflammatory therapy and aerosol inhalation
Trial: 26162646
Drug: Daikenchuto (15.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daikenchuto (15.0 g/day, 5 g three times a day)
Trial: 23323673
Drug: 0.3 g
RxNorm normalized name: sorbitol 0.3 GM Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g kg(‐1) body mass sodium bicarbonate (NaHCO3)
Trial: 23323673
Drug: 0.1 g
RxNorm normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 g kg(‐1) body mass sodium chloride (placebo)
Trial: 17468868
Drug: Fondaparinux 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 0.75 mg
Trial: 17468868
Drug: Fondaparinux 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 1.5 mg
Trial: 17468868
Drug: Fondaparinux 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 3.0 mg
Trial: 14535871
Drug: 13C‐methacetin breath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13C‐methacetin breath test (75 mg per os)
Trial: 11085191
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (5 mg/kg/d of ZnSO4)
Trial: 3325260
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg, twice daily for a mean duration of 8.77 days
Trial: 3325260
Drug: Ofloxacin 600
RxNorm normalized name: ofloxacin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 600 mg, twice daily for a mean duration of 8.77 days
Trial: 3325260
Drug: Ofloxacin 800
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin 800 mg, twice daily for a mean duration of 8.77 days
Trial: 29444690
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg NBMI
Trial: 29444690
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg NBMI
Trial: 24445732
Drug: 6-monthly follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-monthly follow-up with the SFP program (group A)
Trial: 20526195
Drug: GHB at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB at doses of 0.32 g/70 kg
Trial: 20526195
Drug: GHB at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB at doses of 0.56 g/70 kg
Trial: 20526195
Drug: GHB at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB at doses of 0.75 g/70 kg
Trial: 20526195
Drug: GHB at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB at doses of 1.0 g/70 kg
Trial: 20526195
Drug: GHB at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB at doses of 1.8 g/70 kg
Trial: 20526195
Drug: GHB at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB at doses of 2.4 g/70 kg
Trial: 20526195
Drug: GHB at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB at doses of 3.2 g/70 kg
Trial: 20526195
Drug: GHB at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB at doses of 0.32-3.2 g/70 kg
Trial: 18427285
Drug: Tetradecylthioacetic acid
RxNorm normalized name: Tetradecylthioacetic acid
DrugBank: Tetradecylthioacetic acid (DB18802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetradecylthioacetic acid (TTA) 200 mg
Trial: 18427285
Drug: Tetradecylthioacetic acid
RxNorm normalized name: Tetradecylthioacetic acid
DrugBank: Tetradecylthioacetic acid (DB18802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetradecylthioacetic acid (TTA) 600 mg
Trial: 18427285
Drug: Tetradecylthioacetic acid
RxNorm normalized name: Tetradecylthioacetic acid
DrugBank: Tetradecylthioacetic acid (DB18802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetradecylthioacetic acid (TTA) 1000 mg
Trial: 12826549
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.1 mg (Group I)
Trial: 18575162
Drug: Psoas compartment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psoas compartment block with ropivacaine 0.475% 25 mL (Group II)
Trial: 12826549
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (Group I)
Trial: 7578986
Drug: GM-CSF mouthwash
RxNorm normalized name: axatilimab-csfr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF mouthwash (0.01, 0.1, 1.0 or 10 mcg/ml)
Trial: 7578986
Drug: GM-CSF mouthwash
RxNorm normalized name: axatilimab-csfr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF mouthwash (various doses)
Trial: 2197002
Drug: Propofol 6
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 6 mg.kg‐1.hr‐1 and nitrous oxide 50% in oxygen
Trial: 2197002
Drug: Propofol 9
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 9 mg.kg‐1.hr‐1 with 100% oxygen
Trial: 2197002
Drug: Thiopentone 4
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 4 mg.kg‐1 and nitrous oxide 50% in oxygen with enflurane 1%
Trial: 21790620
Drug: Self-help book
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-help book (cognitive behavioral therapy for insomnia)
Trial: 15319567
Drug: Average QOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average QOL during treatment
Trial: 9286887
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg rectal acetaminophen
Trial: 9286887
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg rectal acetaminophen
Trial: 9286887
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg rectal acetaminophen
Trial: 9286887
Drug: Recommended dose
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended dose of 10-15 mg/kg rectal acetaminophen
Trial: 9286887
Drug: Initial dose
RxNorm normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose recommendation
Trial: 3549010
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg single oral dose of ciprofloxacin
Trial: 3549010
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg single oral dose of ciprofloxacin
Trial: 22289549
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day rosuvastatin
Trial: 23523089
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (RT and Tamoxifen)
Trial: 20434199
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS), 200 microg once daily
Trial: 18836092
Drug: Multifactorial strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactorial strategy of pain management (n = 107) including anesthesic patch, specified vaccines, child education, parental accompaniment, and distraction with soap bubbles
Trial: 10695097
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg nimesulide beta cyclodextrin